PR Newswire: news distribution, targeting and monitoring
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
ICO THERAPEUTICS (SCT: ICO)
0.3250 CAD  UNCHANGED
Streaming Delayed Price  /  Updated: 8:29 PM EDT, May 21, 2013  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3250
Today's Range 0.3250 - 0.3250
52wk Range 0.3400 - 0.8500
Shares Outstanding 54,727,627
Dividend Yield N/A
Featured News
More News
Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?"
April 23, 2013
from PR Newswire
Isaac Kobrin, M.D. Joins IMMUNE Pharmaceuticals' Board of Directors
November 29, 2011
-- Former Chief Medical Officer at Actelion Pharmaceuticals Read More
from PR Newswire

Featured News
Read More
iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema
September 26, 2011
from PR Newswire
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
September 13, 2011
from PR Newswire
iCo Therapeutics Provides Phase 1 Diabetic Macular Edema (DME) Clinical Trial Update and Phase 2 Trial Guidance
December 11, 2009
from PR Newswire
iCo Therapeutics Closes $1.3 Million Private Placement
February 09, 2009
from PR Newswire
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Advanced Search
Search
  
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire